Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

D. F. Bavaro; Carlo D. Di; P. Zuccala; F. Bai; F. Incardona; A. Battisti; S. Giache; E. Salomoni; R. Gagliardini; Simona Di Giambenedetto; M. Pecorari; M. Zazzi; Luca A. De; A. Bezenchek; Caputo S. Lo

doi:10.1080/23744235.2018.1544423

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

D. F. Bavaro, Carlo D. Di, P. Zuccala, F. Bai, F. Incardona, A. Battisti, S. Giache, E. Salomoni, R. Gagliardini, Simona Di Giambenedetto, M. Pecorari, M. Zazzi, Luca A. De, A. Bezenchek, Caputo S. Lo^*

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

letter, not available

Lingua originale	Inglese
pagine (da-a)	234-239
Numero di pagine	6
Rivista	Infectious Diseases
Volume	51
Numero di pubblicazione	3
DOI	https://doi.org/10.1080/23744235.2018.1544423
Stato di pubblicazione	Pubblicato - 2019

All Science Journal Classification (ASJC) codes

Immunologia e Microbiologia Generali
Microbiologia (medica)
Malattie Infettive

Keywords

Antiretroviral Therapy
Atazanavir Sulfate
Darunavir
HIV
HIV Infections
Highly Active
Humans
Lamivudine
Ritonavir

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1080/23744235.2018.1544423

Altri file e collegamenti

Cita questo

Bavaro, D. F., Di, C. D., Zuccala, P., Bai, F., Incardona, F., Battisti, A., Giache, S., Salomoni, E., Gagliardini, R., Di Giambenedetto, S., Pecorari, M., Zazzi, M., De, L. A., Bezenchek, A., & Lo, C. S. (2019). Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort. Infectious Diseases, 51(3), 234-239. https://doi.org/10.1080/23744235.2018.1544423

@article{4ab17566ce4b4c3c8e29fe683dab07a7,

title = "Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort",

abstract = "letter, not available",

keywords = "Antiretroviral Therapy, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Highly Active, Humans, Lamivudine, Ritonavir, Antiretroviral Therapy, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Highly Active, Humans, Lamivudine, Ritonavir",

author = "Bavaro, {D. F.} and Di, {Carlo D.} and P. Zuccala and F. Bai and F. Incardona and A. Battisti and S. Giache and E. Salomoni and R. Gagliardini and {Di Giambenedetto}, Simona and M. Pecorari and M. Zazzi and De, {Luca A.} and A. Bezenchek and Lo, {Caputo S.}",

year = "2019",

doi = "10.1080/23744235.2018.1544423",

language = "English",

volume = "51",

pages = "234--239",

journal = "Infectious Diseases",

issn = "2374-4235",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

Bavaro, DF, Di, CD, Zuccala, P, Bai, F, Incardona, F, Battisti, A, Giache, S, Salomoni, E, Gagliardini, R, Di Giambenedetto, S, Pecorari, M, Zazzi, M, De, LA, Bezenchek, A & Lo, CS 2019, 'Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort', Infectious Diseases, vol. 51, n. 3, pagg. 234-239. https://doi.org/10.1080/23744235.2018.1544423

TY - JOUR

T1 - Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

AU - Bavaro, D. F.

AU - Di, Carlo D.

AU - Zuccala, P.

AU - Bai, F.

AU - Incardona, F.

AU - Battisti, A.

AU - Giache, S.

AU - Salomoni, E.

AU - Gagliardini, R.

AU - Di Giambenedetto, Simona

AU - Pecorari, M.

AU - Zazzi, M.

AU - De, Luca A.

AU - Bezenchek, A.

AU - Lo, Caputo S.

PY - 2019

Y1 - 2019

N2 - letter, not available

AB - letter, not available

KW - Antiretroviral Therapy

KW - Atazanavir Sulfate

KW - Darunavir

KW - HIV

KW - HIV Infections

KW - Highly Active

KW - Humans

KW - Lamivudine

KW - Ritonavir

KW - Antiretroviral Therapy

KW - Atazanavir Sulfate

KW - Darunavir

KW - HIV

KW - HIV Infections

KW - Highly Active

KW - Humans

KW - Lamivudine

KW - Ritonavir

UR - https://publicatt.unicatt.it/handle/10807/140089

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85060471824&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060471824&origin=inward

U2 - 10.1080/23744235.2018.1544423

DO - 10.1080/23744235.2018.1544423

M3 - Article

SN - 2374-4235

VL - 51

SP - 234

EP - 239

JO - Infectious Diseases

JF - Infectious Diseases

IS - 3

ER -

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

Abstract

All Science Journal Classification (ASJC) codes

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo